Online inquiry

IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14640MR)

This product GTTS-WQ14640MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets DLL3 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_016941.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10683
UniProt ID Q9NYJ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14640MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7285MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-008
GTTS-WQ9723MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ8387MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ3979MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ15802MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ14037MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aLAG367
GTTS-WQ3964MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ13754MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN 1500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW